5T4

Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer

Retrieved on: 
목요일, 2월 2, 2023
American depositary receipt, Communication, TAAS, Tumor microenvironment, IND, VC, 5T4, Acquisition, ADSS, Cancer, TAA, Antigen, ADS, Drug resistance, Sale, NK, Patient, Neoplasm, Person, Escape Room, Knowledge, Prospectus, Vaccine, Pharmaceutical industry, Security (finance)

REHOVOT, Israel, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that it has entered into an agreement for the acquisition of Immunorizon Ltd., a private company developing potential multi-specific T and NK cell engager oncology therapies that selectively activate the immune response within the tumor microenvironment. The acquisition will provide Purple Biotech with an expanded portfolio of investigational tri-specific antibody compounds that target multiple antigens and offer the potential to further expand to additional targets.

Key Points: 
  • The acquisition will provide Purple Biotech with an expanded portfolio of investigational tri-specific antibody compounds that target multiple antigens and offer the potential to further expand to additional targets.
  • 5T4 is a well-known target that has been validated by multiple pre-clinical and clinical programs.
  • The acquisition will also provide Purple Biotech with additional preclinical assets targeting other TAAs through this technology platform.
  • “We are delighted to add Immunorizon’s portfolio of tri-specific antibodies to our drug development pipeline,” said Gil Efron, CEO of Purple Biotech.

Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

Retrieved on: 
일요일, 1월 8, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, District court, Colorectal cancer, Growth, Large-cell lung carcinoma, Renal cell carcinoma, Catalent, Roche, Nivolumab, Calendar, Therapeutic index, Arm, Head, 5T4, FDA, Antibody, IO, Neck, DC, SIRP, ANDA, Prostate, CD47, Absorption, Ipilimumab, Safety, Webcast, Control, Software, Investigational New Drug, Thyroid cancer, Pharmacokinetics, RCC, Survival analysis, News, Biomarker, CDK7, Breast, Patient, CRC, Tumor microenvironment, ADC, Allele, Conference, Pivotal, Liver, Health insurance, Insurance, Pharmaceutical industry, Vaccine, Exelixis, IND

The preliminary 2022 financial information presented in this press release has not been audited and is subject to change.

Key Points: 
  • The preliminary 2022 financial information presented in this press release has not been audited and is subject to change.
  • The complete Exelixis Fourth Quarter and Full Year 2022 Financial Results are planned for release after market on Tuesday, February 7, 2023.
  • Exelixis President and Chief Executive Officer Michael M. Morrissey, Ph.D., will provide a corporate overview and discuss the company’s preliminary fourth quarter and full year 2022 financial results, 2023 financial guidance, and key priorities and milestones for 2023 during the company’s presentation at the J.P. Morgan Healthcare Conference beginning at 8:15 p.m.
  • To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

Retrieved on: 
월요일, 5월 2, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Head, Drug discovery, IND, Gaps, Hart–Scott–Rodino Antitrust Improvements Act, Nasdaq, Breast cancer, Pancreatic cancer, Research, Tumor microenvironment, HNSCC, Patient, Moa, Program, Inflammation, Large-cell lung carcinoma, Cancer, Trinket, NSCLC, MD, Multimedia, 5T4, Fibroblast, Science, Entrepreneurship, Cell, NK, Therapy, B cell, Pharmaceutical industry, Dragonfly

Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications.
  • Under the agreement, Gilead will receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001.
  • The agreement also grants Gilead options, after the completion of certain preclinical activities, to license exclusive, worldwide rights to develop and commercialize additional NK cell engager programs using the Dragonfly Tri-specific NK Engager (TriNKET) platform.
  • TriNKETs are activators of the innate and adaptive immune systems, recruiting NK and cytotoxic T cells into the tumor microenvironment.

Asana BioSciences Announces Dosing of First Patient in Phase 1 Trial of ASN004, a Novel 5T4-Antibody-Drug-Conjugate

Retrieved on: 
금요일, 4월 8, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Janus, DAR, Principal, Motor neuron, Itch, Cough, Neck, Pharmacokinetics, ADC, Clinical research, Cancer, Monomethyl auristatin F, 5T4, Doctor of Philosophy, Head, Asana, Program, Neoplasm, Janus kinase, Pain, LLC, Safety, JAK3, JAK1, TYK2, ATP, SYK, PI3K, Neuron, JAK, Kinase, Atopic dermatitis, JAK2, Patient, Large-cell lung carcinoma, Respiratory disease, Vaccine, Pharmaceutical industry

ASN004 incorporates a novel single-chain Fv-Fc antibody linked to a clinically validated Auristatin F hydroxypropylamide cytotoxic payload, and drug to antibody ratio (DAR) of approximately 10-12.

Key Points: 
  • ASN004 incorporates a novel single-chain Fv-Fc antibody linked to a clinically validated Auristatin F hydroxypropylamide cytotoxic payload, and drug to antibody ratio (DAR) of approximately 10-12.
  • In preclinical cancer models, a single dose of ASN004 achieved complete and durable tumor regression leading to tumor-free survivors.
  • Asana is focused on discovery and development of novel targeted investigational medicines in immunology/inflammation and oncology.
  • In a Phase 1b study in atopic dermatitis patients, topical application of ASN008 showed rapid onset of pruritus relief (NCT03798561).

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting

Retrieved on: 
목요일, 3월 24, 2022
Cell, Therapy, Protein engineering, Neutralizing antibody, 5T4, AACR, Poster, American Association, CD3, Neoplasm, Therapeutic index, Bristol Myers Squibb, Tissue, MHC, Association, Annual general meeting, MTC, Nasdaq, Toxic shock syndrome, NK, SAN, Patient, TPBG, Pharmaceutical industry, Vaccine, Chiesi Farmaceutici

"We believe that both of these platforms are foundational to our continued efforts aimed at growing our emerging pipeline of therapeutic candidates in oncology."

Key Points: 
  • "We believe that both of these platforms are foundational to our continued efforts aimed at growing our emerging pipeline of therapeutic candidates in oncology."
  • Details on poster presentations are shared below:
    Posters will be available on-demand on the AACR website for attendees ( www.aacr.org ) beginning at 12:00 PM CDT on April 8, 2022 until July 13, 2022.
  • Upon release at AACR, the scientific posters will be accessible through Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations .
  • Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases.